The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia ...

Click the FOLLOW button to be the first to know about this artist's upcoming lots, sold lots, exhibitions and articles ...

Prognosis is the prediction of the probable outcome of an individual's current medical condition. A prognosis is made on the basis of the normal course of a disease, the individual's physical and ...